Carisma Therapeutics Inc. a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the expansion of its in vivo chimeric antigen receptor macrophage and monocyte collaboration with Moderna, Inc. to include the nomination of two targets for the treatment of autoimmune diseases.

Carisma Therapeutics Inc.是一家专注于发现和开发创新免疫疗法的临床阶段生物制药公司，今天宣布扩大其与Moderna，Inc.的体内嵌合抗原受体巨噬细胞和单核细胞合作，包括提名两个治疗自身免疫性疾病的靶标。

Carisma retains all rights in autoimmune disease beyond the two nominated targets, which will be exclusively partnered with Moderna.Under this expanded collaboration, Carisma and Moderna will leverage Carisma's proprietary CAR-M technology and Moderna's mRNA/LNP platform to develop novel in vivo macrophage engineering approaches in the nominated autoimmune disease targets.

Carisma保留了两个提名目标之外的自身免疫性疾病的所有权利，这两个目标将与Moderna独家合作。在这一扩大的合作下，Carisma和Moderna将利用Carisma专有的CAR-M技术和Moderna的mRNA/LNP平台，在指定的自身免疫性疾病靶标中开发新的体内巨噬细胞工程方法。

Carisma will receive research funding and is eligible to receive development, regulatory, and commercial milestone payments, plus royalties on net sales of any products that are commercialized under the collaboration agreement. Carisma will be responsible for the discovery and optimization of development candidates, while Moderna will lead the clinical development and commercialization of therapeutics resulting from the agreement.'We are excited to expand our collaboration with Moderna into the realm of autoimmune diseases,' said Steven Kelly, President and Chief Executive Officer of Carisma.

Carisma将获得研究资金，并有资格获得开发、监管和商业里程碑付款，以及根据合作协议商业化的任何产品的净销售额的版税。Carisma总裁兼首席执行官史蒂文·凯利（StevenKelly）说，我们很高兴将与Moderna的合作扩展到自身免疫性疾病领域。

'The nomination of the two autoimmune targets is a significant milestone in our mission to harness the power of macrophages to treat a broader range of diseases. Our innovative CAR-M technology has the potential to revolutionize the treatment landscape for patients suffering from these debilitating conditions.''We are excited to build on the progress of advancing in vivo CAR-M therapies with Carisma by expanding beyond oncology,' said Lin Guey, PhD, CSO of Therapeutic Resea.

“这两个自身免疫靶标的提名是我们利用巨噬细胞的力量治疗更广泛疾病的使命中的一个重要里程碑。我们创新的CAR-M技术有可能彻底改变患有这些衰弱疾病的患者的治疗格局。”。